Adaptive Biotechnologies Corp vs Sony Group Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Sony Group Corp trades at $23.7 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 34.3× Adaptive Biotechnologies Corp's market cap, and Sony Group Corp pays a 0.67% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SONY | |
|---|---|---|
Market Cap | $4.04B | $138.43B |
Sector | Health | Technology |
52-Week High | $25.45 | $30.26 |
52-Week Low | $12.30 | $19.32 |
Enterprise Value | $4.10B | $136.35B |
Dividend Yield | — | 0.67% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →